Evidence map›Paper›PMID 40896364›Full record

ArticleMolecular therapy. Oncology2025

Targeting MDM2 homodimer and heterodimer disruption with DRx-098D in

Sean F Cooke, Thomas A Wright, Gillian Lappin, Elka Kyurkchieva, Yuan Yan Sin, Jiayue Ling, Alina Zorn, Bria O'Gorman, William Banyard, Chih-Jung Chang and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Sean F CookeCollege of Medical, Veterinary and Life Sciences, University of Glasgow, G12 8QQ Glasgow, UK.
Thomas A WrightCollege of Medical, Veterinary and Life Sciences, University of Glasgow, G12 8QQ Glasgow, UK.
Gillian LappinCollege of Medical, Veterinary and Life Sciences, University of Glasgow, G12 8QQ Glasgow, UK.
Elka KyurkchievaCollege of Medical, Veterinary and Life Sciences, University of Glasgow, G12 8QQ Glasgow, UK.
Yuan Yan SinCollege of Medical, Veterinary and Life Sciences, University of Glasgow, G12 8QQ Glasgow, UK.
Jiayue LingCollege of Medical, Veterinary and Life Sciences, University of Glasgow, G12 8QQ Glasgow, UK.
Alina ZornCollege of Medical, Veterinary and Life Sciences, University of Glasgow, G12 8QQ Glasgow, UK.
Bria O'GormanCollege of Medical, Veterinary and Life Sciences, University of Glasgow, G12 8QQ Glasgow, UK.
William BanyardCollege of Medical, Veterinary and Life Sciences, University of Glasgow, G12 8QQ Glasgow, UK.
Chih-Jung ChangCollege of Medical, Veterinary and Life Sciences, University of Glasgow, G12 8QQ Glasgow, UK.
Helen WheadonPaul O'Gorman Leukaemia Research Centre, University of Glasgow, G11 0YN Glasgow, UK.
Danny T HuangCancer Research UK - Scotland Institute, G61 1BD Glasgow, UK.
George S BaillieCollege of Medical, Veterinary and Life Sciences, University of Glasgow, G12 8QQ Glasgow, UK.
Connor M BlairCollege of Medical, Veterinary and Life Sciences, University of Glasgow, G12 8QQ Glasgow, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Novel pharmacological strategies capable of inhibiting pro-oncogenic MDM2 beyond its p53-dependent functions represent increasingly attractive therapeutic strategies to treat solid and hematological cancers that are dependent upon MDM2/MDMX, regardless of

Indexed as

dimerizationdisruptor peptideMDM2MDMXMT: Regular IssueTP53 mutant cancer

Identifiers

PMID40896364
PMCPMC12395054

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.